Novo Nordisk stock heads into earnings week as Wegovy pill scripts top 26,000
Novo Nordisk Class B shares closed at 369.6 Danish crowns on Friday, down 0.8 crown, as investors awaited the company’s 2025 financial statement set for Feb. 4. U.S. prescriptions for the new Wegovy pill surged to 26,109 in the week ending Jan. 23, up sharply from its launch. Leadership changes in China and rising competition from AstraZeneca add pressure ahead of earnings.